Replies to post #201860 on Biotech Values

[masterlongevity]

i would imagine it has to be 3%, and I assume that yardstick (or whatever it is) has been provided to $SRPT

[DewDiligence]

SRPT—Caveat emptor re “phase-3b” offerings:

http://finance.yahoo.com/news/sarepta-therapeutics-announces-proposed-offering-201900782.html